Abstract: A detector and a method for the detection of nitro-containing compounds, such as explosives, is described. Detection is by observing the quenching of the photoluminescence of functionalized silicon nanocrystals, such as amine-functionalized silicon nanocrystals, oligonucleotide-functionalized silicon nanocrystals, oligomer or monolayer alkyl-functionalized silicon nanocrystals, aromatic polymer-functionalized silicon nanocrystals and alkanoic acid-functionalized silicon nanocrystals by the nitro-containing compounds. The detector and method are non-toxic, portable, rapid and straightforward and therefore are amenable for convenient on-site detection of nitro-containing compounds.
Type:
Application
Filed:
December 23, 2014
Publication date:
July 9, 2015
Applicant:
THE GOVERNORS OF THE UNIVERSITY OF ALBERTA
Inventors:
Jonathan G. C. Veinot, Mita Dasog, Christina Gonzalez, Muhammed Iqbal, Tapas Purkait, Reid Erickson
Abstract: Phosphoranimide-metal catalysts and their role in C—O bond hydrogenolysis and hydrodeoxygenation (HDO) are disclosed. The catalysts comprise of first row transition metals such as nickel, cobalt and iron. The catalysts have a metal to anionic phosphoranimide ratio of 1:1 and catalyze C—O bond hydrogenolyses of a range of oxygen-containing organic compounds under lower temperature and pressure conditions than those commonly used in industrial hydrodeoxygenation.
Type:
Grant
Filed:
December 21, 2012
Date of Patent:
June 9, 2015
Assignee:
Governors of the University of Alberta
Inventors:
Jeffrey Camacho Bunquin, Jeffrey Mark Stryker
Abstract: The invention relates generally to methods and compositions for the cryopreservation and/or vitrification of tissue including articular cartilage and the preparation of said tissue for clinical or research use, including but not limited to joint replacement and the treatment and prevention of osteoarthritis.
Type:
Application
Filed:
May 20, 2014
Publication date:
June 4, 2015
Applicant:
The Governors of the University of Alberta
Abstract: A hydrogen absorbing and desorbing material formed by co-deposition of magnesium with a catalyst for the kinetic absorption and desorption of hydrogen. A hydrogen absorbing and desorbing material formed of an alloy of magnesium with a catalyst for the kinetic absorption and desorption of hydrogen in which the catalyst for the kinetic absorption and desorption of hydrogen forms a dispersed amorphous or nanocrystalline phase in the magnesium. A hydrogen absorbing and desorbing material having a catalytic surface formed by a process comprising the steps of depositing a layer of tantalum on the hydrogen absorbing and desorbing material and depositing a layer of palladium on the layer of tantalum. A hydrogen absorbing and desorbing material comprises a multilayer film having at least two layers of magnesium and at least two layers of catalyst for the kinetic absorption and desorption of hydrogen, in which the multilayer film comprises alternating layers of magnesium and catalyst.
Type:
Grant
Filed:
August 18, 2011
Date of Patent:
June 2, 2015
Assignee:
The Governors of the University of Alberta
Inventors:
David Mitlin, Beniamin Zahiri, Mohsen Danaie, Babak Shalchi Amirkhiz, XueHai Tan, Erik Luber, Christopher Harrower, Peter Kalisvaart
Abstract: Nanoparticle catalyst compositions and methods for preparation of same are described. The nanoparticle catalysts are platinum-free and are useful in effecting selective ring-opening reactions, for example in upgrading heavy oil. The catalyst may be of monometallic composition, or may comprise an alloyed or core-shell bimetallic composition. The nanoparticles are of controlled size and shape.
Abstract: The present invention generally relates to use of compounds and compositions as a chemosensitizers and/or radiosensitizers and/or inhibitors of PNKP phosphatase activity. The present invention provides pharmaceutical combinations and/or a pharmaceutically acceptable salt thereof, kits containing such compounds and/composition and methods of using such compounds and/or compositions.
Type:
Grant
Filed:
June 4, 2010
Date of Patent:
May 26, 2015
Assignees:
THE GOVERNORS OF THE UNIVERSITY OF ALBERTA, ALBERTA HEALTH SERVICES
Inventors:
Michael Weinfeld, Dennis G. Hall, Feridoun Karimi-Busheri, Gary Kenneth Freschauf, Todd Randall Mereniuk
Abstract: A method for desorption of bitumen from clay particles. Also a method for the desorption of asphaltenes from clay particles and a method for the desorption of bituminous fractions from mature fine tails (MFT). The method for desorption of bitumen from clay particles involves interacting, in a suitable organic solvent, a clay-bitumen composite with a compound capable of stabilizing the bitumen in the organic solvent and adsorbing to clay particles such that the compound replaces the bitumen in the clay-bitumen composite. A substantial amount of the compound that is capable of stabilizing the bitumen in the organic solvent is recovered with the clay particles, while the bitumen is released. Similarly, the method for desorption of asphaltenes from clay particles also involves interacting a clay-asphaltene composite with a compound capable of stabilizing the asphaltenes in an organic solvent, recovering the compound with the clay particles, and releasing the asphaltenes into solution.
Type:
Application
Filed:
November 19, 2013
Publication date:
May 21, 2015
Applicant:
GOVERNORS OF THE UNIVERSITY OF ALBERTA
Inventors:
Christian DETELLIER, Sadok LATAIEF, Jonathan FAFARD, Gustave Kenne DEDZO
Abstract: Two- and three-terminal molecular electronic devices with ballistic electron transport are described. For example, a two-terminal molecular electronic device includes a conductor 1 layer/molecule 1 layer/conductor2 layer junction, wherein the total thickness of the molecule 1 layer and the conductor2 layer is less than or approximately equal to the mean free path of a charge carrier traveling in the two layers, and wherein ballistic transport can occur for some fraction of a plurality of charge carriers in the two layers.
Type:
Grant
Filed:
September 16, 2011
Date of Patent:
May 5, 2015
Assignees:
The Governors of the University of Alberta, National Research Council of Canada
Inventors:
Richard L. McCreery, Adam Johan Bergren
Abstract: Huntington's disease (HD) is a neurodegenerative disorder caused by the expansion of a polyglutamine stretch in the protein huntingtin (Htt). HD neurons are dysfunctional at multiple levels and have increased susceptibility to stress and apoptotic stimuli. As described therein there is provided compound(s), composition(s), methods and/or kits for the treatment and/or diagnosis of Huntington's disease.
Type:
Grant
Filed:
August 20, 2010
Date of Patent:
May 5, 2015
Assignee:
The Governors of the University of Alberta
Abstract: The present application relates to glycoengineered outer membrane vesicles obtained from recombinant, gram-negaetive bacteria comprising hetereologous DNA encoding an enzyme or enzymes that produce a heterologous glycan that replaces all or a portion of the naturally-occurring O antigen in the lipopolysaccharides of the bacteria. Also provided by the present application are immunogenic compositions and vaccines prepared from the glycoengineered outer membrane vesicles expressing the heterologous glycans at their surface.
Type:
Application
Filed:
April 26, 2013
Publication date:
April 30, 2015
Applicant:
The Governors of the University of Alberta
Inventors:
Mario Feldman, Nancy Price, Fatima Garcia-Quintanilla, Maria Veronica Ielmini
Abstract: Phosphoranimide-metal catalysts are disclosed. The catalysts comprise first row transition metals such as nickel, cobalt or iron. The hydrocarbon-soluble catalysts have a metal to anionic phosphoranimide ratio of 1:1, and have no inactive bulk phase and no dative ancillary ligands. The electronic state of the clusters can be adjusted to optimize catalytic activity for a range of commercially important reductive transformations, including hydrodesulfurization. A method of synthesis of these catalysts by anionic metathesis of a halide substituted precursor followed by oxidation is also disclosed.
Type:
Grant
Filed:
May 21, 2013
Date of Patent:
April 7, 2015
Assignee:
Governors of the University of Alberta
Inventors:
Houston J. S. Brown, Jeffrey Mark Stryker, Dominque M. Hebert
Abstract: The present invention provides for a novel system and method for amplification and detection of nucleic acids within a microfluidic device wherein multiple nucleotides capable of priming PCR are present within the system and substantially sequestered within separate hydrogel posts therein.
Type:
Grant
Filed:
August 29, 2011
Date of Patent:
March 24, 2015
Assignee:
The Governors of the University of Alberta
Abstract: Taxanes are widely used in the treatment of breast cancer, although there are currently no validated predictive markers for taxane responsiveness. While the mechanism by which taxanes induce mitotic arrest is well documented, the signaling pathway that links mitotic arrest to cell death, is ill-defined. As described herein, the BH3-only protein Bad and Bik are prognostic indicators for overall survival after adjuvant taxane chemotherapy and a predictive marker for taxane responsiveness.
Type:
Grant
Filed:
November 19, 2010
Date of Patent:
March 17, 2015
Assignees:
The Governors of the University of Alberta, Alberta Health Services
Inventors:
Ing Swie Goping, John R. Mackey, D. Alan Underhill
Abstract: The present invention is directed to methods for tailoring the work function of electrodes in organic electronics using interfacial modifiers comprising functionalized semiconducting polymers and/or small molecules.
Type:
Application
Filed:
June 21, 2012
Publication date:
March 12, 2015
Applicants:
NATIONAL RESEARCH COUNCIL OF CANADA, THE GOVERNORS OF THE UNIVERSITY OF ALBERTA
Inventors:
Brian Worfolk, Qun Chen, Jillian Buriak
Abstract: Described herein are methods and systems that can be used to induce immunologic tolerance to non-self antigens. The methods and systems comprise introducing a tolerogen comprising at least one immunogenic non-self antigen coupled to a carrier, wherein the immunogenic antigen can be a foreign or endogenous antigen or fragments thereof. The non-self antigen can be selected from the group consisting of carbohydrate antigens, full-length antigenic proteins, and fragments and combinations thereof, while the carrier can be selected from nanoparticles and stents. Tolerogen compositions are also provided and can be used to induce immunologic tolerance to non-self antigens. These methods, systems and compositions are particularly advantageous since they can be used to allow for the extension of the window of safety for immunologically-incompatible transplantations to patients who are growing past the age of infancy.
Type:
Grant
Filed:
December 11, 2009
Date of Patent:
March 10, 2015
Assignee:
The Governors Of The University Of Alberta
Inventors:
Lori Jeanne West, Todd Lambert Lowary, Jillian Mary Buriak, Brian Daly, Mylvaganam Jeyakanthan, Peter John Meloncelli, Vincent Arthur Wright, Anne Margaret Cooper
Abstract: A method of forming a waveguide, the method comprising the steps of: forming a multilayer stack of light guiding layers; and delaminating the multilayer stack between at least two of the light guiding layers to form a waveguide between the light guiding layers; in which the patterned region has converging sides and the waveguide is tapered, the multilayer stack having increased transmissivity at a region corresponding to a selected thickness of the waveguide. A tapered waveguide is also disclosed, comprising: a multilayer stack of light guiding layers; the multilayer stack defining a channel between at least a first waveguiding layer and a second waveguiding layer; the channel having a diminishing thickness in a first direction; and at least one of the first waveguiding layer and the second waveguiding layer having a region of increased transmissivity adjacent a selected thickness of the core. Methods for the use of the tapered waveguide as an optical coupler or spectrometer are also disclosed.
Abstract: Described herein are methods for producing fuels and solvents from fatty acid resources. In general, the pyrolysis products of fatty acids are extracted in order to remove residual fatty acids and produce very pure hydrocarbon compositions composed of alkanes and alkenes. The fatty acids removed from the extraction step can be further pyrolyzed to produce additional hydrocarbons or, in the alternative, the fatty acids can be isolated and used in other applications. Also disclosed herein are fuels and solvents produced by the methods described herein.
Type:
Grant
Filed:
February 24, 2011
Date of Patent:
March 10, 2015
Assignee:
The Governors of the University of Alberta
Abstract: A quantum device is provided that includes controllably quantum mechanically coupled dangling bonds extending from a surface of a semiconductor material. Each of the controllably quantum mechanically coupled dangling bonds has a separation of at least one atom of the semiconductor material. At least one electrode is provided for selectively modifying an electronic state of the controllably quantum mechanically coupled dangling bonds. By providing at least one additional electron within the controllably quantum mechanically coupled dangling bonds with the proviso that there exists at least one unoccupied dangling bond for each one additional electron present, the inventive device is operable at least to 293 degrees Kelvin and is largely immune to stray electrostatic perturbations. Room temperature operable quantum cellular automata and qubits are constructed thereform.
Type:
Application
Filed:
July 31, 2014
Publication date:
March 5, 2015
Applicants:
The Governors of the University of Alberta, National Research Council of Canada
Inventors:
Gino A. Dilabio, Robert A. Wolkow, Jason L. Pitters, Paul G. Piva
Abstract: Provided in the following specification are precursors or synthons that are useful for the synthesis of various arabinose based chemical and radiochemical derivatives of nitroimidazole-containing azomycin arabinosides, such as radioiodinated 1-#-D-(5-deoxy-5-[I*]-iodoarabinofuranosyl)-2-nitroimidazole (*IAZA), and radiofluorinated 1-#-D-(5-deoxy-5-[18F]-iodoarabinofuranosyl)-2-nitroimidazole (18FAZA). Such compounds are useful in imaging, therapy, or radiotherapy. Further, various syntheses of said precursors/synthons and the incorporation of said precursors/synthons into kits is provided. The precursors/synthons provided herein allow for an improved and facile manufacturing process for nitroimidazole-containing azomycin arabinosides.
Type:
Grant
Filed:
June 27, 2011
Date of Patent:
March 3, 2015
Assignees:
The Governors of the University of Alberta, Alberta Health Services
Inventors:
Piyush Kumar, Leonard Wiebe, Alexander McEwan